Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 3/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334024 | 1.00 | PSMB1 (0.49) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL334686 | 1.00 | PSMB1 (0.49) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL334371 | 1.00 | PSMB1 (0.49) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL4451480 | 1.00 | PSMB1 (0.49) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL334449 | 1.00 | PSMB1 (0.49) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL10027658 | 0.96 | PSMB1 (0.47) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL6033453 | 0.95 | PSMB1 (0.46) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL335159 | 0.95 | PSMB1 (0.46) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL334152 | 0.95 | PSMB1 (0.47) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL6035522 | 0.95 | CAPN1 (0.48) | PSMB1CAPN1CAPN2NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169289-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2015-10-27 | — | — | US | disclosed |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | STRONGBONE AB (SE) | 2014-08-28 | — | — | US | disclosed |
| US-8748370-B2 | Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation | STRONGBONE AB (SE) | 2014-06-10 | — | — | US | disclosed |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2012-05-03 | — | — | US | disclosed |
| WO-2010147547-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2010-12-23 | — | — | WO | disclosed |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | NEOBIOTICS AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | NEOBIOTICS AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-7691805-B2 | Antimicrobial compounds | NEOBIOTICS AB (SE) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, SOST, BMP1 | PSMB1 892/4885CAPN1 1948/4885CAPN2 1886/4885 |
| US-20140243274-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, CALCRL, ARG1 | PSMB1 1070/4885CAPN1 2260/4885CAPN2 2212/4885 |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | ARG1, C1R, ARG2 | PSMB1 2231/4885CAPN1 4097/4885CAPN2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.